Triphase Accelerator Corporation
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Triphase Accelerator Corporation
Bristol bought Celgene following multiple pipeline setbacks, but the biotech giant made positive progress recently that the big pharma will be expected to continue.
While the proposed Bristol/Celgene merger nears an April vote, Celgene continues a recent spate of deal-making, paying $25m up front to Exscientia to discover small molecule candidates for cancer and autoimmune disease.
Genentech will pay $120m up front to co-develop Xencor’s preclinical IL-15 candidate; deal also includes IL-15 R&D. Taiho licenses lung cancer candidate to Cullinan; Celgene and Triphase partner again.
Celgene reported second quarter sales growth for key assets in its commercial portfolio, including a recovery for Otezla, and prepared investors for a deluge of data in the second half of 2017.
- Other Names / Subsidiaries
- Nereus Pharmaceuticals Inc.
- Triphase Research & Development Corp.